Previous 10 | Next 10 |
2023-11-28 11:56:40 ET More on SPDR S&P 500 ETF Trust: 2024 Analyst Outlook: Mott Capital On Market Volatility, The Fed, And Investor Challenges And Opportunities The Week On Wall Street: Holiday Edition Broad Turn In Weekly Momentum Bodes Well For Stocks ...
2023-11-07 12:51:35 ET Gainers: PaxMedica ( PXMD ) +78% . Jaguar Global Growth Corp I ( JGGC ) +62% . Transmedics Group ( TMDX ) +54% . Baiyu Holdings ( BYU ) +48% . Fathom Digital Manufacturing Corporation ( FATH ) +46% . Ko...
2023-11-07 01:15:42 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2023 Earnings Call Nov 06, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
2023-11-07 00:20:24 ET MacroGenics, Inc. (MGNX) Q3 2023 Earnings Conference Call November 6, 2023 16:30 ET Company Participants Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call ...
2023-11-06 17:13:37 ET More on MacroGenics MacroGenics' Undervalued Potential In Oncology Therapeutics MacroGenics 2023 Q2 - Results - Earnings Call Presentation MacroGenics Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on MacroGenics ...
2023-11-06 16:08:57 ET More on MacroGenics MacroGenics' Undervalued Potential In Oncology Therapeutics MacroGenics, Inc. 2023 Q2 - Results - Earnings Call Presentation MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rati...
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., N...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
MacroGenics Inc. (MGNX) is expected to report $-0.03 for Q3 2023
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial r...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...